← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Abviro, Llc
Bethesda, MD
$38,306,544
Total funding
2
Grants
Funding over time
peak $9.4M · FY2016–24$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$38,306,544 · 2
By mechanism
N01$38,306,544 · 2
Investigators at Abviro, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases$6,990,472
N01 · FY2024 · AI
A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.$5,381,917
N01 · FY2019 · AI
A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.$4,676,851
N01 · FY2017 · AI
A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.$4,676,851
N01 · FY2017 · AI
DEVELOPMENT OF A BROAD-SPECTRUM THERAPEUTIC$2,600,780
N01 · FY2022 · AI
A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.$2,576,151
N01 · FY2016 · AI
A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.$2,576,151
N01 · FY2016 · AI
A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.$1,939,315
N01 · FY2018 · AI
A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.$1,939,314
N01 · FY2018 · AI
Development of Therapeutics for DENGUE VIRUS$1,752,967
N01 · FY2023 · AI
DEVELOPMENT OF A BROAD-SPECTRUM THERAPEUTIC$1,593,363
N01 · FY2020 · AI
DEVELOPMENT OF A BROAD-SPECTRUM THERAPEUTIC$1,593,363
N01 · FY2020 · AI
DEVELOPMENT OF A BROAD-SPECTRUM THERAPEUTIC$9,049
N01 · FY2023 · AI